Reprosia is not a reporting tool. It is the AI-native foundation that makes pharmaceutical analyses trustworthy, reproducible, and submission-ready by design.
Three layers: your existing R environment, the Reprosia AI audit engine, and regulatory-ready output. No migration required.
Existing scripts, packages, data pipelines. RStudio, Posit, CI/CD. No change required.
Audit, validate, lock, certify. AI-powered compliance scanning and environment management.
eCTD-ready packages, IQ/OQ/PQ docs, CDISC outputs, estimand documentation.
AI-assisted IQ/OQ/PQ validation of your R environment and packages. Every function call, parameter, and result documented automatically with cryptographic audit trails compliant with 21 CFR Part 11 and GxP requirements.
Guaranteed reproducibility across environments, teams, and time. Locked package versions, containerised execution, and continuous drift monitoring ensure your analysis at database lock matches your analysis at submission — to the decimal.
Regulatory-ready outputs for FDA and EMA submissions. CDISC-compatible data structures, ICH E9(R1) estimand documentation, and pre-built eCTD templates — generated directly from your existing R analysis pipeline, with full traceability back to source data.
Integrates with existing R workflows in minutes. Works alongside RStudio, Posit Workbench, and CI/CD pipelines. No migration required.
reproducr regulogAutomatic scanning for reproducibility risks, undocumented dependencies, environment drift, and compliance gaps — before they become submission failures.
lineager estimandrFreeze your environment at database lock. Generate automated IQ/OQ/PQ validation documentation and full audit reports ready for agency review.
IQ / OQ / PQOne command to generate your eCTD-compatible submission package. Full audit trail, reproducibility proof, and regulatory documentation included.
FDA EMA ICHReprosia wraps around your existing R infrastructure. No rip and replace.
Built against real regulatory requirements from the ground up.
| Standard | Coverage | Feature |
|---|---|---|
| 21 CFR Part 11 | Full | Electronic records, audit trail, digital signatures, access controls |
| ICH E9(R1) | Full | Estimand specification, intercurrent event strategies, SAP documentation |
| GCP / GLP | Full | Good Practice workflow integration, validation SOPs, change control |
| CDISC SDTM | Full | Study data tabulation model output, define.xml, reviewer's guide |
| CDISC ADaM | Full | Analysis dataset model, ADSL, ADAE, ADTTE derivation tracking |
| eCTD | Full | Module 5 statistical output packaging, bookmarking, hyperlinking |
| EMA Guidelines | Full | CHMP statistical guidelines, conditional approval requirements |
| GDPR | Full | EU data residency, processing records, data subject rights |
We work directly with pharma and biotech teams. Request early access and we'll be in touch within 48 hours.
Or reach us at ndoh@reprosia.com